BACKGROUND: Numerous problems are associated with biochemical androgen receptor (AR) assay performance and interpretation in prostatic cancer. The purpose of this study was to determine if a novel immunocytochemical AR assay performed on intact tissue sections would prove useful in prognosticating endocrine response and survival. METHODS: A prospective study was done on 63 prostatic carcinomas maintained in liquid nitrogen for over a decade. The study used the peroxidase-antiperoxidase system and a polyclonal anti-AR antibody. RESULTS: Marked tissue and cellular heterogeneity of nuclear AR was apparent. A cut-off of 10% AR-positive cells maximized assay prognostic efficiency. Frequency of positivity was 48% and correlated significantly with endocrine response (p = 0.03), time to progression (p = 0.0016), and survival (p = 0.02), but not with grade, stage, or ethnicity. CONCLUSIONS: This AR assay could be prognostically useful in the clinical management of prostate cancer and is suitable for use in the community hospital laboratory.
BACKGROUND: Numerous problems are associated with biochemical androgen receptor (AR) assay performance and interpretation in prostatic cancer. The purpose of this study was to determine if a novel immunocytochemical AR assay performed on intact tissue sections would prove useful in prognosticating endocrine response and survival. METHODS: A prospective study was done on 63 prostatic carcinomas maintained in liquid nitrogen for over a decade. The study used the peroxidase-antiperoxidase system and a polyclonal anti-AR antibody. RESULTS: Marked tissue and cellular heterogeneity of nuclear AR was apparent. A cut-off of 10% AR-positive cells maximized assay prognostic efficiency. Frequency of positivity was 48% and correlated significantly with endocrine response (p = 0.03), time to progression (p = 0.0016), and survival (p = 0.02), but not with grade, stage, or ethnicity. CONCLUSIONS: This AR assay could be prognostically useful in the clinical management of prostate cancer and is suitable for use in the community hospital laboratory.
Authors: J A de Winter; J Trapman; A O Brinkmann; W J Boersma; E Mulder; F H Schroeder; E Claassen; T H van der Kwast Journal: J Pathol Date: 1990-04 Impact factor: 7.996
Authors: T Demura; N Kuzumaki; A Oda; H Fujita; N Taniguchi; Y Asano; N Takayama; K Nonomura; T Koyanagi Journal: Am J Clin Oncol Date: 1988 Impact factor: 2.339
Authors: V E Quarmby; W C Beckman; D B Cooke; D B Lubahn; D R Joseph; E M Wilson; F S French Journal: Cancer Res Date: 1990-02-01 Impact factor: 12.701
Authors: L P Pertschuk; H E Rosenthal; R J Macchia; K B Eisenberg; J G Feldman; S H Wax; D S Kim; W F Whitmore; J I Abrahams; E Gaetjens; G J Wise; H W Herr; J P Karr; G P Murphy; A A Sandberg Journal: Cancer Date: 1982-03-01 Impact factor: 6.860